RT Journal Article
SR Electronic
T1 THE AIRBORNE CONTAGIOUSNESS OF RESPIRATORY VIRUSES: A COMPARATIVE ANALYSIS AND IMPLICATIONS FOR MITIGATION
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.26.21250580
DO 10.1101/2021.01.26.21250580
A1 Mikszewski, A.
A1 Stabile, L.
A1 Buonanno, G.
A1 Morawska, L.
YR 2021
UL http://medrxiv.org/content/early/2021/01/29/2021.01.26.21250580.abstract
AB Background The infectious emission rate is a critical input parameter for airborne contagion models, but data are limited due to reliance on estimates from chance superspreading events. A predictive estimation approach for the quanta emission rate (ERq) was recently proposed for SARS-CoV-2 using the droplet volume concentration of various expiratory activities. This study assesses the strength of the approach and uses novel predictive estimates of ERq to compare the contagiousness of respiratory pathogens.Methods We applied the predictive approach to SARS-CoV-1, SARS-CoV-2, MERS, measles virus, adenovirus, rhinovirus, coxsackievirus, seasonal influenza virus and Mycobacterium tuberculosis (TB) and compared ERq estimates to values reported in literature. We calculated infection risk in a prototypical classroom and barracks to assess the relative ability of ventilation to mitigate airborne transmission.Results Our median standing and speaking ERq estimate for SARS-CoV-2 (2.6 quanta hour (h)-1) is similar to active, untreated TB (3.1 h-1), higher than seasonal influenza (0.17 quanta h-1), and lower than measles virus (15 quanta h-1). We calculated event reproduction numbers above 1 for SARS-CoV-2, measles virus, and untreated TB in both the classroom and barracks for an activity level of standing and speaking at low, medium and high ventilation rates of 2.3, 6.6 and 14 liters per second per person, respectively.Conclusions Our predictive ERq estimates are consistent with the range of values reported over decades of research. In congregate settings, current ventilation standards are unlikely to control the spread of viruses with upper quartile ERq values above 10 quanta h-1, such as SARS-CoV-2, indicating the need for additional control measures.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere was no funding supporting the work presented.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A